The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition by Louis S. Matza et al.
The Fatigue Associated with Depression Questionnaire (FAsD):
responsiveness and responder definition
Louis S. Matza • Kathleen W. Wyrwich •
Glenn A. Phillips • Lindsey T. Murray •
Karen G. Malley • Dennis A. Revicki
Accepted: 16 February 2012 / Published online: 9 March 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Purpose The Fatigue Associated with Depression Ques-
tionnaire (FAsD) was developed to assess fatigue and its
impact among patients with depression. The purpose of this
study was to examine the questionnaire’s responsiveness to
change and identify a responder definition for interpreta-
tion of treatment-related changes.
Methods Data were collected at baseline and at 6 weeks
from patients with depression starting treatment with a new
antidepressant.
Results Of the 96 participants, 55.2% were women, with
a mean age of 43.4 years. The total score and both sub-
scales demonstrated statistically significant change with
moderate to large effect sizes (absolute values C0.76).
FAsD change scores were significantly correlated with
change on the Brief Fatigue Inventory (r C 0.73;
p \ 0.001). FAsD mean change scores discriminated
among patient subgroups differing by degree of improve-
ment in patient- and clinician-reported fatigue and
depression. Responder definition for the two subscales and
total score (0.67, 0.57, 0.62) was estimated primarily based
on mean change among patients who reported a small but
important improvement in fatigue.
Discussion The FAsD was responsive to change, and the
responder definition may be used when interpreting treat-
ment-related change. Results add to previous findings
suggesting the FAsD is a useful measure of fatigue among
patients with depression.
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Introduction
Research on treatment of depression has increasingly
focused on a symptom-specific approach, often targeting
residual symptoms that persist after other symptoms have
improved [1–6]. Residual symptoms have been shown to
predict relapse of depressive episodes [4, 7–10], and they
contribute to functional impairment even after other
depressive symptoms have improved following pharmaco-
logical or psychological treatment [8, 9, 11–13]. Much of the
research on residual symptoms has focused on fatigue,
which is one of the most common symptoms of major
depressive disorder [14–16]. Several studies suggest that
fatigue is frequently a residual symptom, persisting in
roughly 20 to 38% of patients who have remitted following
pharmacological treatment or psychotherapy [9, 17, 18].
There is a substantial and growing body of research focusing
on fatigue associated with depression because of its preva-
lence, its resistance to treatment, and its association with
impairment in social and work functioning [19–23].
Despite the clinical importance of fatigue associated
with depression, there was no available patient-reported
outcome (PRO) instrument designed specifically to assess
fatigue and its impact among patients with depression [24].
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Therefore, the Fatigue Associated with Depression Ques-
tionnaire (FAsD) was recently developed to address this
gap in assessment tools for patients with depression [25].
Depression symptom measures often include an item
assessing fatigue [26–28], but they do not provide a thor-
ough multidimensional assessment of this construct, and
they are therefore unlikely to adequately capture fatigue
and its impact. In focus groups conducted when drafting
the FAsD, patients reported a range of the 13 items of the
FAsD were designed to capture a more thorough spectrum
of fatigue experience and impact that is important to
patients with depression.
Generic instruments, designed to be completed by
respondents regardless of medical or psychiatric condition,
are available for a more detailed assessment of fatigue [29,
30]. However, there is growing awareness that PRO
instruments must demonstrate content validity and good
measurement properties in the specific target population in
order to be appropriate for assessment of treatment out-
comes [31, 32], and the generic fatigue measures do not
meet these standards for patients with depression. For
example, although the FAsD has been shown to correlate
strongly with the commonly used generic Brief Fatigue
Inventory (BFI), there are important differences between
the two measures in content validity. Whereas the BFI was
designed for use in cancer patients [29], the FAsD was
developed based on direct input of patients with depression
as well as clinicians who treat depression [25]. As a result
of this careful approach to establishing content validity, the
FAsD items assess the specific types of fatigue and its
impact that are likely to be experienced by patients with
depression, and the items use words shared by patients
during qualitative research. Therefore, unlike the generic
instruments, the FAsD has established content validity in
the target population, and the appropriate wording and
content of the items for this specific population may lead to
greater measurement precision. For example, the specific
relevance of the items to this population led to the clear
two-factor model based on a factor analysis conducted to
derive FAsD subscales [25]. In this analysis, there was a
clear distinction between items assessing experience and
items assessing impact. Therefore, the FAsD allows for
specific assessment of the impact of fatigue, in contrast to
the BFI, which has been shown to yield only a global score
supported by a strong single-factor model fit [29]. In sum,
although there is clearly some overlap between the FAsD
and generic instruments assessing fatigue, no other instru-
ment has demonstrated content validity for the detailed
assessment of this clinically important symptom and its
impact among patients with depression [25].
The FAsD was developed following recommendations
in the Food and Drug Administration PRO Guidance
Document [31]. The items were initially drafted and
refined based on literature review and qualitative research
with clinicians and patients diagnosed with depression.
Then, a psychometric validation study was conducted to
identify subscales and examine reliability and validity of
the measure. In this validation study, the FAsD demon-
strated good factor structure, internal consistency reliabil-
ity, test–retest reliability, and construct validity [25]. The
purpose of the current study is to examine the question-
naire’s responsiveness to change and identify a responder
definition that will assist with interpretation of treatment-
related change.
Responsiveness is the extent to which a health status
measure accurately detects change in a patient’s condition
over time [32–34]. Demonstration of this measurement
property is necessary for a PRO measure to be considered
fit for the purpose of ‘‘identifying differences in scores
over time in both individuals and groups who have
changes with respect to the measured concept’’ [31]. Tests
for responsiveness typically include effect size statistics as
well as correlations of change scores with change in
previously validated measures or indicators of the concept
of interest. Responsiveness testing may also include
comparison of change scores among patient subgroups
categorized by an indicator of change in the relevant
concept, such as patients’ or clinicians’ perceptions of
change.
Once responsiveness has been demonstrated, establish-
ing guidelines for the interpretation of PRO change scores
can assist in recognizing when an important shift in
patients’ health status has occurred. This step of instrument
development was often characterized as identifying the
minimally important difference (MID). However, the 2009
Food and Drug Administration (FDA) PRO Guidance has
eliminated the term MID from their directives for PRO
development.
Instead of the MID, the FDA now requests a responder
definition that is ‘‘the individual patient PRO score change
over a predetermined time period that should be interpreted
as a treatment benefit’’ when a PRO instrument is used
in clinical trials [31]. The FDA recommends that the
responder definition should be determined empirically
through anchor-based methods using data from the target
population, with supportive evidence from distribution-
based statistics. The anchors, which should be easier to
interpret than the PRO measure, may be clinical indicators,
patient ratings of change, or clinician ratings of change.
Once a responder definition is ascertained, the percentage
of responders achieving change at or beyond this threshold
in each treatment arm of a clinical trial can be compared to
facilitate the evaluation and communication of PRO results
to patients, physicians, and providers.




Data were collected from patients with depression at
seven privately owned psychiatry clinics specializing in
behavioral and mental health in the United States. Inclu-
sion criteria included: age C18 years old; clinical diag-
nosis of depression; and current symptoms of depression
as indicated by a score on the 8-item Patient Health
Questionnaire (PHQ-8) of C5, the recommended cutpoint
for mild depression severity [35]. Patients were required
to have started treatment with a new antidepressant within
seven days prior to their first study visit. This treatment
decision must have been made for clinically indicated
reasons independent of the current study or any other
study. Exclusion criteria were diagnosis of bipolar disor-
der; receiving treatment with a mood stabilizer or anti-
psychotic; or diagnosed with the following medical
conditions that could cause fatigue: chronic fatigue syn-
drome, sleep apnea, cancer, multiple sclerosis, or HIV.
Patients returned for a second visit six weeks after the
initial study visit. The study protocol was approved by an
independent ethics review committee (Ethical Review
Committee, Inc.; ID#: 436-07-08), and all participants
provided informed consent.
A total of 119 patients were enrolled. Patients were
excluded from the current analysis if they did not attend
Visit 2 (n = 18) or if they attended Visit 2 on a date that
was outside the required window of 42 ± 7 days after Visit
1 (n = 5). Thus, there were 96 patients in the analysis
sample.
Measures
All measures described below were administered at both
study visits unless stated otherwise.
Fatigue Associated with Depression Questionnaire (FAsD)
This 13-item patient-reported questionnaire was designed
to assess fatigue associated with depression in the past
week [25]. Three scores are computed: a 6-item fatigue
experience subscale (items: fatigued, tired, exhausted, lack
of energy, physically weak, and feeling like everything
requires too much effort), a 7-item fatigue impact subscale
(items assess impact on household chores; family rela-
tionships; enjoyable activities; social activities with
friends; self-care; intimate relationships; and productivity
at work or school), and a total score (all 13 items). Items 12
(impact on intimate relationships) and 13 (impact on pro-
ductivity at work or school) are not applicable to all
respondents, so these items are not answered in some cases.
The fatigue experience items are rated on a 5-point scale
with response options of ‘‘never,’’ ‘‘rarely,’’ ‘‘sometimes,’’
‘‘often,’’ and ‘‘always.’’ The impact items are rated on a
5-point scale with response options of ‘‘not at all,’’ ‘‘a lit-
tle,’’ ‘‘somewhat,’’ ‘‘quite a bit,’’ and ‘‘very much.’’ The
two subscales and the total score are computed as the mean
of all answered items within each scale, and each scale
score has a possible range of 1 to 5, with higher scores
representing greater fatigue.
Brief Fatigue Inventory
The brief fatigue inventory (BFI) includes three items
assessing the severity of fatigue and six items assessing the
degree to which fatigue has interfered with a range of
domains, including mood, walking ability, and enjoyment
of life [29]. The BFI was designed primarily for cancer
patients, with a structure derived from the Brief Pain
Inventory. The total score is computed as the mean of
responses to all items. These scores may range from 0 to
10, with higher scores representing greater fatigue.
Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) [36] was developed to
determine the level of daytime sleepiness, and it was
administered in the current study so that analyses could
explore the relationship between fatigue and sleepiness.
Patients rate the chance of dozing or sleeping during eight
activities. Scores are based on the sum of responses to the
eight items. Scores may range from 0 to 24, with higher
scores representing greater sleepiness.
Clinical Global Impression-Severity
The Clinical Global Impression-Severity Scale (CGI-S)
was completed by clinicians to assess their overall
impression of the severity of the patient’s depressive ill-
ness. The score ranges from 1 (normal, not at all ill) to 7
(among the most extremely ill patients) [37].
Patient perception of change
At Visit 2, patients reported their perceptions of change in
fatigue. Patients were asked ‘‘Since you began your current
antidepressant treatment about 6 weeks ago, has there been
an overall change in your fatigue?’’ Patients responded by
choosing one of seven response options: much worse;
moderately worse; a little worse; stayed about the same;
hardly any change; improved in a small but important way;
moderately improved; and much improved.
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Clinician perception of change
Clinicians completed two items at Visit 2. The first item
asked clinicians to rate change in patients’ fatigue since
beginning a new antidepressant treatment at the time of
Visit 1. The second item asked whether there had been a
change in the patient’s depression. Clinicians responded to
both questions by choosing one of seven response options:
much worse; moderately worse; a little worse; stayed about
the same, hardly any change; improved in a small but
important way; moderately improved; and much improved.
Clinicians did not see patients’ responses to any ques-
tionnaires prior to completing these items.
Demographic and clinical forms
All participants completed a brief demographic and clinical
form. Clinicians completed a clinical information form for
each participant, reporting diagnoses, severity of depres-
sion, comorbid conditions, and medications.
Statistical analysis
Descriptive statistics summarizing demographic and clini-
cal characteristics were summarized in terms of frequen-
cies and percentages for categorical variables as well as
means and standard deviations for continuous variables.
Statistical procedures for assessing responsiveness
of the FAsD
Clinician- and patient-rated measures were used to assess
the responsiveness of the FAsD. Pearson correlations were
performed to assess the degree of association between the
FAsD change scores and change in the BFI and ESS. Cor-
relation coefficient absolute values were interpreted as small
(0.1 to 0.29), moderate (0.3 to 0.49), and large (0.5 and
greater) based on the guidelines proposed by Cohen [38].
Patients were categorized into groups based on their
degree of change as indicated by three variables: (1) change
from Visit 1 to Visit 2 on the CGI-S, (2) clinician perceptions
of change in fatigue, and (3) patient perceptions of change in
fatigue. Then, the mean FAsD scores of these groups were
compared using either t tests or general linear models
(GLMs) with Scheffe’s post hoc pairwise comparisons,
while controlling for age, gender, and antidepressant
medication class. Medication class was a three-level cate-
gorical variable: selective serotonin reuptake inhibitor
(SSRI), n = 51; serotonin–norepinephrine reuptake inhibi-
tor (SNRI), n = 37; and other, n = 8. The eight patients in
the ‘‘other’’ group were treated with either a norepineph-
rine–dopamine reuptake inhibitor (NDRI; n = 7) or a
combination of an NDRI and an SSRI. The GLMs were also
conducted using the BFI as the dependent variable to
examine whether results were similar to those for the FAsD.
Effect size is a statistic that represents change as a
standard unit of measurement [39]. For the subscales and
total score of the FAsD, effect sizes were calculated as the
difference in mean score from baseline to follow-up divi-
ded by the standard deviation of baseline scores for all
subjects (mean score Time 1—mean score Time 2/standard
deviation of baseline scores). This effect size was inter-
preted as small (0.20), moderate (0.50), or large (0.80)
following the guidelines proposed by Cohen [38].
Statistical procedures for identifying the responder
definition of the FAsD
The responder definition for each the FAsD subscales and
total score was determined using anchor-based methods,
supported by distribution-based approaches [31, 34]. The
primary method used the mean change scores of patients
who reported experiencing a small but important change in
fatigue from Visit 1 to Visit 2. A similar secondary analysis
was conducted using the anchor of clinician-reported
change in fatigue. Beyond these anchor-based methods, the
state changes for each FAsD subscale and total scores were
considered when deriving the responder definitions. ‘‘State
changes’’ are defined as the amount of change in a subscale
or total score that results from one shift up or down in the
response options for only one item [40].
Two distribution-based methods for examining respon-
der definition were calculated using Visit 1 data. First, the
standard error of measurement (SEM) was computed as the
standard deviation of an observed score related to its reli-
ability (SD * sqrt of [1—reliability]). The SEM has been
linked to estimates of minimally important change stan-
dards [41]. The SEM is expressed in the original metric of
the instrument, which can facilitate ease of interpretation.
Although test–retest reliability is the most appropriate
estimate of reliability for SEM calculations used to
approximate an important change over time [42], internal
consistency reliability was used for these analyses because
reproducibility estimates could not be determined for the
current sample. The second distribution-based method was
the half standard deviation, which has been shown to
provide a reasonable approximation of a meaningful
change in patient-reported outcome instruments [43].
Results
Sample description
Table 1 presents demographic and clinical characteristics
(N = 96). Participants were 55.2% women, with a mean
354 Qual Life Res (2013) 22:351–360
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age of 43.4 years. The sample was somewhat diverse with
regard to racial background (e.g., 41.7% white, 27.1%
African-American, and 16.7% Hispanic), marital status
(e.g., 32.3% married, 32.3% single, 19.8% divorced), and
employment status (e.g., 32.3% working full-time, 28.1%
unemployed, 16.7% disabled, and 13.5% working part-
time). The majority of the sample was living with a spouse,
partner, family, or friends (78.1%) and had received at least
some college education (65.7%). The mean age at the time
of first depression diagnosis was 33.3 years. The majority
of participants reported no comorbid medical conditions
(61.5%). Among those reporting a comorbid medical
condition, the most common conditions were hypertension
(18.8%) and arthritis (11.5%). Based on medical chart
review, a majority of the participants did not have any
current or previous psychiatric diagnoses other than
depression (81.3%). The most common current or previous
comorbid psychiatric conditions were anxiety disorders
(13.5%). At Visit 1, the majority of the sample was con-
sidered to have depression of at least moderate symptom
severity, as rated by clinicians completing the CGI-S.
These CGI-S ratings were as follows: borderline ill (n = 2;
2.2%), mildly ill (n = 4; 4.4%), moderately ill (n = 62;
68.1%), markedly ill (n = 21; 23.1%), and severely ill
(n = 2; 2.2%).
All participants began treatment with a new antide-
pressant (Table 1) within seven days prior to their first
study visit. The most commonly prescribed classes of
medications were SSRIs (54.2%) and SNRIs (38.5%). The
most frequent prescribed medications were escitalopram
(30.2%), desvenlafaxine (15.6%), duloxetine (14.6%), and
venlafaxine (8.3%).
Descriptive statistics: FAsD change
FAsD mean scores were lower at Visit 2 (total score =
2.84) than Visit 1 (total score = 3.53), indicating improve-
ment in depression-related fatigue (Table 2). Mean score
changes on the two FAsD subscales also reflected a
decrease from Visit 1 to Visit 2 (decreases of 0.73 on the
impact subscale and 0.67 on the experience subscale). The
FAsD scales had moderate to large effect sizes from Visit 1
to Visit 2 (-0.76 for the impact subscale; -0.84 for the
experience subscale; and -0.84 for the total score).
Because the final two items of the FAsD impact scale
are designed to be skipped by some patients for whom the
items are not applicable (i.e., patients who do not attend
work/school or have an intimate relationship), descriptive
statistics were also conducted for the instrument without
inclusion of these final two items. The mean impact
subscale score was 3.47 at Visit 1 and 2.73 at Visit 2
(mean change score = -0.74). The mean total score was
3.55 at Visit 1 and 2.85 at Visit 2 (mean change
score = -0.70). These values are almost the same as
those presented in Table 2, which has scores computed
with all 13 items.
Table 1 Demographic and clinical characteristics
Characteristic Statistics
(N = 96)




Racial background (n, %)
Asian or Pacific Islander 9 (9.4%)
Black, not of Hispanic origin 26 (27.1%)
Hispanic 16 (16.7%)
White, not of Hispanic origin 40 (41.7%)
Other 5 (5.2%)
Marital status (n, %)
Married 31 (32.3%)
Not married 65 (67.7%)
Living/domestic situation (n, %)
Living alone 18 (18.8%)
Living with spouse, partner, family, friends 75 (78.1%)
Other 3 (3.1%)
Employment status (n, %)
Full-time work 31 (32.3%)
Part-time work 13 (13.5%)
Other 52 (54.2%)






Antidepressant medications started within one week of Visit 1 (n, %)a
NaSSA: (mirtazapine) 1 (1.0%)
NDRI: (bupropion) 7 (7.3%)
SNRI (desvenlafaxine, duloxetine, venlafaxine) 37 (38.5%)
SSRI (citalopram, escitalopram, fluoxetine,
fluvoxamine, paroxetine, sertraline)
52 (54.2%)
a Of the 96 patients, 95 received only one new antidepressant, while
one patient received combination treatment with two antidepressants
(bupropion and citalopram)
NaSSA noradrenergic and specific serotonergic antidepressant/tetra-
cyclic antidepressant
NDRI norepinephrine–dopamine reuptake inhibitor/aminoketone
SNRI serotonin–norepinephrine reuptake inhibitor
SSRI selective serotonin reuptake inhibitor or serotonin-specific re-
uptake inhibitor
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Assessing responsiveness through comparisons to clinical
measures of change
Changes in FAsD subscale and total scores were signifi-
cantly (all p \ 0.001) correlated with changes in the BFI
and the ESS (Table 2). Correlations of the FAsD scales
with the BFI ranged from 0.73 to 0.80. While still statis-
tically significant, correlations with the ESS were weaker,
ranging from 0.36 to 0.42.
FAsD mean change scores discriminated among groups
of patients were categorized based on patient perceptions
of change in fatigue (Table 3). In general, greater
improvement in patient perceptions of fatigue was associ-
ated with greater improvement in the FAsD. For example,
the FAsD total score and experience subscale score dem-
onstrated significantly greater average change in the group
that perceived improvements than in the groups that
reported their fatigue as staying about the same or
worsening (all p \ 0.05). Analyses with patients catego-
rized based on clinician-perceived change in fatigue yiel-
ded similar results. T tests were conducted to compare
FAsD scores between patients who improved and those
who did not improve (i.e., worsened or no change), based
on clinician judgment. All FAsD scales demonstrated sig-
nificantly greater change in patients who improved than in
patients who did not improve (between-group differences
were 0.53 for the experience subscale, 0.61 for the impact
subscale, and 0.57 for the total score; all p \ 0.05).
FAsD total and subscale mean change scores also
significantly discriminated among groups of patients
categorized based on degree of change in the clinician-
rated CGI-S. Patients were categorized into three groups
based on degree of CGI-S change: improved by 2 or 3
levels, improved by 1 level, and worsened/no change.
Greater improvements in CGI-S ratings were associated
with greater reduction in mean FAsD scores. For
Table 2 FAsD change scores: t tests comparing Visit 1 score to Visit 2 score and correlations with change in other patient-reported measures





Visit 1 to Visit 2
Mean (SD)
t value Pearson correlations of FAsD
change with change in other measures
BFI ESS
FAsD experience subscale score 3.61 (0.80) 2.95 (0.96) -0.67 (1.02) -6.4*** 0.73*** 0.36***
FAsD impact subscale score 3.45 (0.95) 2.73 (1.16) -0.73 (1.08) -6.6*** 0.73*** 0.40***
FAsD total score 3.53 (0.83) 2.84 (1.01) -0.69 (0.97) -7.0*** 0.80*** 0.42***
N for means and t tests = 96; N for correlations with BFI = 95; N for correlations with ESS = 92
FAsD Fatigue Associated with Depression Questionnaire
BFI Brief Fatigue Inventory
ESS Epworth Sleepiness Scale
*** p \ 0.001
Table 3 Analysis of variance comparing FAsD and BFI change scores among groups differing by patient perception of change in fatigue
Change in FAsD
scales
Three groups categorized based on patient perception



















-0.96 (0.15) -0.25 (0.25) 0.08 (0.32) 3.8** \0.001 A*, B**
FAsD impact subscale
score
-1.03 (0.16) -0.45 (0.27) -0.10 (0.35) 2.5* 0.011 B*
FAsD total score -1.00 (0.14) -0.34 (0.24) -0.00 (0.30) 3.6** \0.001 A*, B**
BFI -2.78 (0.34) -0.66 (0.58) -0.34 (0.74) 3.8** \0.001 A**, B**
a Model includes age, gender, and antidepressant medication class as covariates
b Pairwise comparisons: A = improved versus about the same; B = improved versus worsened
FAsD Fatigue Associated with Depression Questionnaire
BFI Brief Fatigue Inventory
* p \ 0.05; ** p \ 0.01
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example, the FAsD total score decreased by 1.26 points
among patients who improved by 2 or 3 CGI-S levels,
0.72 points among patients who improved by 1 CGI-S
level, and -0.37 points among patients who did not
improve in the CGI-S. Pairwise comparisons indicate that
the FAsD impact subscale and total score demonstrated
significantly greater average change in the improved by
2 or 3 levels group than in the no improvement group
(all p \ 0.05). The FAsD impact subscale also demon-
strated significantly greater mean change in the improved
by 2 or 3 levels group than in the improved by 1 level
group (p \ 0.05).
The ANOVA models were also conducted with the BFI,
rather than the FAsD, as the dependent variable. The pat-
tern of mean change scores and statistically significant
differences between groups followed the same patterns as
those resulting from models with the FAsD total score.
Patient perception of greater improvement and greater
improvement in CGI-S ratings were both associated with
greater decreases in the BFI. As indicated in Table 3, the
BFI demonstrated significantly greater change in the group
that perceived improvements than in the groups that
reported their fatigue as staying about the same or wors-
ening (all p \ 0.01).
Responder definition
The primary method for estimating responder definition
was based on the mean FAsD change among the 20
patients who reported experiencing a small but important
change in fatigue from the first study visit to the second
(Table 4). The mean FAsD change scores for this subgroup
were -0.66 (experience subscale), -0.51 (impact sub-
scale), and -0.59 (total score). Analyses using clinician-
reported anchors provide additional support for the
responder definition (Table 4). Among the 17 patients
viewed by clinicians as having a small but important
change in fatigue, FAsD mean change scores were -0.37
(experience subscale), -0.25 (impact subscale), and -0.31
(total score). The smaller FAsD mean change scores cor-
responding to clinician-rated changes over time suggest
that the patient-based change scores are a conservative
estimate of the responder definition (i.e., the clinician-rated
changes suggest that a smaller responder definition may be
appropriate).
Kappa statistics were calculated to examine the degree
of agreement between patient perception of change in
fatigue and clinician perception of change (the two vari-
ables used in Table 4) [44]. The simple kappa of 0.27 (95%
confidence interval: 0.13 to 0.40) and the weighted Kappa
of 0.49 (95% confidence interval: 0.38 to 0.61) suggest a
small-to-moderate level of agreement between patient and
clinician ratings.
Distribution-based methods also suggest that the patient-
based change scores are a conservative estimate of
responder definition. For the experience subscale, impact
subscale, and total score, the half SD values were 0.40,
0.48 and 0.41, respectively. SEM values, using internal
consistency reliability estimates from the current sample,
were 0.30, 0.36 and 0.24.
The state change defined as the amount of change in a
subscale, or total score that results from one shift up or
down in the response options for only one item, was cal-
culated for each FAsD subscale and the total scores. For the
FAsD experience subscale with six items, a shift of one
response option on a single item corresponds to a change of
0.17 in the subscale score. For the impact subscale with
seven items, a shift of one response option on a single item
corresponds to a change of 0.14 in the subscale score.
Finally, the FAsD total score with 13 items has a state
change of 0.08 points. Because the FAsD scores can only
change by increments in multiples of these state changes,
the responder definitions for the FAsD experience subscale,
impact subscale, and total score were conservatively set at
0.67, 0.57 and 0.62, respectively.
Discussion
Results of all analyses indicate that the FAsD was
responsive to change. The total score and both subscales
demonstrated statistically significant improvement from
Visit 1 to Visit 2, with effect sizes suggesting that these
changes were in the moderate to large range. In addition,
FAsD change scores discriminated among groups of
patients who differed by degree of improvement in patient-
and clinician-reported fatigue and depression symptom
severity.
Current results also provide an initial indication of a
responder definition that may be used when interpreting
treatment-related change in the FAsD. Using the 20
patients with ratings of a small but important improvement
in fatigue after six weeks of treatment, the mean change
scores in this study were -0.66, -0.51, and -0.59,
respectively, for the FAsD experience subscale, impact
subscale, and total score. These mean change scores are
likely to be conservative estimates of a responder defini-
tion, because they exceed the magnitude of values provided
by supportive analyses, including mean change scores
among 17 patients viewed by clinicians as having a small
but important change in fatigue, as well as the half standard
deviation and the SEM of these scales. Based on these
results and the magnitude of a state change in the FAsD
experience subscale, a responder definition of 0.67 is rec-
ommended for this subscale (i.e., a score decrease of at
least 0.67 on this subscale). This threshold corresponds to a
Qual Life Res (2013) 22:351–360 357
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shift of four response options across the six items in the
subscale. Similarly, the responder definition for the FAsD
impact subscale was identified as 0.57, which corresponds
to a shift of four response options across the seven subscale
items. Finally, the responder definition for the FAsD total
score was identified as 0.62, which corresponds to a shift of
eight response options across the 13 items.
The strong correlations between FAsD change scores
and BFI change scores suggest that these two question-
naires capture change in similar aspects of fatigue. How-
ever, there are two key differences between the
questionnaires. First, the FAsD was developed and vali-
dated specifically for patients with depression, suggesting
that it may be uniquely fit for use in this target population.
In contrast, the BFI was designed for use in cancer patients,
with a general structure derived from the Brief Pain
Inventory [29]. Second, the FAsD subscales provide sep-
arate assessments of fatigue experience and impact,
whereas the BFI yields only a global score [29]. In quali-
tative research conducted when developing the FAsD,
patients with depression have reported that fatigue has a
powerful impact on multiple aspects of their lives [25], and
the FAsD impact scale was designed to quantify this
impact. Therefore, the FAsD has advantages over the BFI
for studies examining change in fatigue among patients
with depression. Furthermore, although correlations with
the BFI are strong (0.73 B r B 0.80), these coefficients
suggest that the BFI explains only 53% of the variation in
the FAsD subscales and 64% of the variation in the FAsD
total score. Therefore, the FAsD captures unique aspects of
fatigue that are not captured by the BFI in this population.
One limitation of the current study is that patients
received treatment in naturalistic clinical settings, rather
than in a controlled clinical trial context. Although all
patients were required to receive a new antidepressant
treatment within 7 days of study enrollment, it is likely that
many aspects of the treatment experience varied among the
seven clinical sites, as well as among clinicians at each site.
Therefore, the generalizability of the current results to the
clinical trial context is not known. Another limitation is
that the current sample size is not large enough to examine
FAsD measurement properties within subgroups of patients
categorized based on their specific pharmacological treat-
ment. Patients in the current study received a wide range of
pharmacological treatments. Some of these medications
may have the potential to exacerbate fatigue, while others
may have the potential to reduce fatigue, and it is possible
that FAsD scores were influenced by these treatments.
Nonetheless, these results support the use of the FAsD in
studies examining change in fatigue, and the FAsD may be
even more responsive to change in a controlled trial with a
standardized treatment approach.
Another factor that could have affected the results is the
missing data at Visit 2. Of the 119 patients who were
Table 4 Estimating the responder definition: FAsD change scores among groups of patients categorized based on change in fatigue






Patient perception of change in fatiguea
Much improved 16 (17.2%) -1.41 (0.99) -1.57 (1.09) -1.50 (0.97)
Moderately improved 30 (32.3%) -0.82 (1.01) -0.88 (1.29) -0.85 (1.09)
Improved in a small but important way 20 (21.5%) -0.66 (0.91) -0.51 (0.75) -0.59 (0.63)
Stayed about the same 17 (18.3%) -0.17 (0.78) -0.32 (0.60) -0.23 (0.62)
A little worse 5 (5.4%) 0.27 (0.76) 0.32 (0.36) 0.30 (0.39)
Moderately worse 3 (3.2%) 0.11 (1.02) 0.00 (0.40) 0.06 (0.64)
Much worse 2 (2.2%) -0.17 (1.41) -0.46 (0.56) -0.33 (0.41)
Clinician perception of change in fatiguea
Much improved 15 (17.9%) -1.24 (1.13) -1.63 (1.16) -1.44 (1.08)
Moderately improved 24 (28.6%) -1.15 (1.02) -1.25 (1.14) -1.20 (1.02)
Improved in a small but important way 17 (20.2%) -0.37 (0.78) -0.25 (0.64) -0.31 (0.56)
Stayed about the same 20 (23.8%) -0.07 (0.74) -0.25 (0.73) -0.15 (0.58)
A little worse 6 (7.1%) -0.44 (0.96) 0.14 (0.24) -0.15 (0.49)
Moderately worse 1 (1.2%) -1.17 (–) -0.07 (–) -0.62 (–)
Much worse 1 (1.2%) -0.83 (–) -0.14 (–) -0.46 (–)
a Of 96 patients, 93 completed the patient perception of change question, and 84 had clinicians who reported perception of change in the
patient’s fatigue
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enrolled in the study, 23 were excluded from the analyses
either because they did not attend Visit 2 (n = 18) or they
attended Visit 2 outside the required window of
42 ± 7 days after Visit 1 (n = 5). Because the goal of this
analysis was to examine change in any instrument over
time, it was essential to have data at a minimum of two
time points. Therefore, no data were imputed for the
missing Visit 2 values. It is possible that the 23 excluded
patients could have had more severe symptoms or less
improvement on average than the 96 included patients.
However, although this potential difference between
included and excluded patients could affect the evaluation
of treatment outcomes, it is unlikely to have a substantial
impact on the current analysis that focused on longitudinal
instrument performance and ascertaining the responder
definition to identify individuals with a treatment benefit.
Because the 96 included patients demonstrated improve-
ment in depression and fatigue, their data are likely to be
sufficient for evaluation of FAsD responsiveness and
responder definition.
In the current study, the responder definition was based
primarily on patients who reported a small but important
change. However, other methodological approaches are
possible. For example, there may be situations when it is
preferable or necessary to use clinicians’ ratings, rather
than patients’ ratings, as the primary anchor of change [45].
Current results indicate that clinicians and patients may
have different perspectives on meaningful change. In the
current sample, 20 patients reported ‘‘small but important’’
change, compared with only 17 patients who had this rating
of change from clinicians. The mean FAsD change scores
were lower for the 17 patients classified to this change
group by clinicians than for the 20 self-classified patients.
These findings suggest that a clinician-based approach
could yield a different responder definition than a patient-
based approach. In addition, ‘‘small but important’’ may
not be the optimal degree or description of change to select
a responder. For some PRO instruments, perhaps a patient-
reported ‘‘moderate improvement’’ response would be a
more appropriate criterion for determining the responder
definition.
Almost all results of the current analysis followed log-
ical and expected patterns, with the exception of some
FAsD change scores presented in Table 4. However, the
unexpected results only occurred in the smaller groups who
reported becoming worse during the study (n B 6) and are
likely to be a function of the small group sizes. All groups
of larger size (i.e., 16–30 patients categorized based on
patient perception; 15–24 patients categorized based on
clinician perception) followed logical patterns, with FAsD
change scores of direction and magnitude that were entirely
consistent with patient-reported and clinician-reported
perception of change in fatigue. Future research with larger
sample sizes may provide stronger support for the use of
the FAsD to assess change over time.
When considered along with previous analyses demon-
strating factor structure, reliability, and validity of the
FAsD, current findings suggest that the FAsD is a useful
measure of fatigue for studies focusing on treatment of
depression. Measures such as the FAsD that allow for a
detailed assessment of individual depressive symptoms are
essential tools for developing a symptom-specific approach
to treatment [3, 4]. By administering symptom-specific
PRO measures, researchers may examine the effects of
medications and other interventions on individual symp-
toms that are particularly relevant for some patients.
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